DHB (Dihydroboldenone / 1-Testosterone)

Dihydroboldenone is the 5-alpha reduced form of Boldenone, structurally analogous to how DHT is the 5-alpha reduced form of testosterone. It binds to the androgen receptor with approximately twice the affinity of testosterone, explaining its high anabolic potency. Being already 5-alpha reduced, it cannot undergo further reduction and therefore has reduced androgenic activity in tissues that express high 5-alpha reductase (skin, prostate, hair follicles). DHB cannot be aromatized to estrogen, producing zero estrogenic side effects. It enhances nitrogen retention, protein synthesis, and promotes lean tissue accrual without the water retention associated with aromatizing compounds.

DHB is most commonly available as the cypionate ester, providing a half-life of approximately 7-9 days. Peak plasma levels occur within 24-48 hours post-injection with gradual decline over the following week. Steady-state is reached after approximately 4-5 weeks. The compound is metabolized hepatically but is not c17-alpha alkylated, posing minimal hepatotoxic risk. Limited pharmacokinetic studies exist compared to more established AAS. The high melting point of the raw compound (approximately 192C) contributes to the PIP issues, as it can precipitate from solution after injection.

• ✓High anabolic potency (approximately 200% that of testosterone)
• ✓No aromatization to estrogen
• ✓Lean, dry muscle gains with zero water retention
• ✓Lower androgenic activity than testosterone (less hair loss, acne, prostate issues)
• ✓Good strength gains relative to mass gained
• ✓Effective at moderate doses (lower required dose than primobolan)
• ✓Enhanced muscle definition and hardness

• ⚠Notorious for severe post-injection pain (PIP) - one of the worst of any injectable AAS
• ⚠Limited availability and research compared to established AAS
• ⚠HPTA suppression requiring PCT
• ⚠Some users report lethargy at higher doses
• ⚠Mild lipid impact
• ⚠Potential for injection site inflammation, lumps, and sterile abscesses from PIP
• ⚠Higher cost due to limited production and supply

Contraindications

• 🚫Individuals intolerant of injection pain
• 🚫Cardiovascular disease
• 🚫Liver disease
• 🚫Limited injection site options (PIP requires large muscle groups)
• 🚫Individuals requiring extensive clinical safety data before use

Begin PCT 10-14 days after the last DHB Cypionate injection. Standard PCT: Nolvadex 20mg/day for 4-6 weeks, or Clomid 50mg/day for 3-4 weeks. DHB is moderately suppressive; recovery is generally manageable with standard protocols. HCG during cycle at standard doses is recommended. Bloodwork 4-6 weeks after PCT to confirm HPTA recovery.

• 1.PIP management is the primary challenge; warming oil to body temperature, injecting slowly (60+ seconds), and using larger muscle groups helps significantly
• 2.Diluting DHB with sterile MCT oil in the same syringe (1:1 ratio) can dramatically reduce PIP at the cost of larger injection volume
• 3.Start at 200mg/week to assess your PIP tolerance before increasing the dose
• 4.DHB provides primobolan-like results at roughly half the dose, making it more cost-effective despite its higher per-mL price
• 5.Some users report that PIP diminishes after 3-4 weeks of consistent use as injection sites adapt
• 6.If PIP is creating visible swelling or redness lasting more than 5-7 days, consider that the product may have contamination issues

1. [1]Friedel A, et al. 17beta-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) pharmacology. Rapid Commun Mass Spectrom. 2006.
2. [2]Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502-521.
3. [3]Dihydroboldenone structure-activity relationship studies. J Med Chem.
4. [4]Community pharmacovigilance data from long-term DHB users. Various bodybuilding harm reduction forums.